Latest News
Oncoinvent reports recruitment milestone in Phase 2 study of Radspherin in ovarian cancer
19 June 2026 - Oncoinvent ASA (Euronext Growth Oslo:ONCIN), a Norway-based clinical-stage radiopharmaceutical company developing innovative treatments for solid cancers, announced on Thursday that its ongoing Phase 2 trial of Radspherin in patients w...
Nortiva Bio launches to develop long-acting oral medicines using LYNX platform
18 June 2026 - Nortiva Bio Inc announced on Thursday its launch as a clinical-stage biopharmaceutical company focused on developing long-acting oral medicines using its proprietary LYNX drug delivery platform.Nortiva is a wholly owned subsidiary of d...
FDA accepts Genentech application for Lunsumio and Polivy combination in large B-cell lymphoma
18 June 2026 - Biotechnology company Genentech, a member of the Roche Group (SIX: RO, ROG) (OTCQX: RHHBY), said on Thursday that the US Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application for subcutaneous Lu...
Getinge launches Fluobeam LS for fluorescence‑guided small‑incision surgery
...
Organon and Samsung Bioepis expand Canada biosimilar partnership with PYZCHIVA
18 June 2026 - US healthcare company Organon (NYSE:OGN) and South Korean biopharmaceutical company Samsung Bioepis Co Ltd announced on Thursday an expansion of their development and commercialisation agreement, granting Organon exclusive commercialis...